Xiong W, et al. – Given the benefit of pulmonary arterial hypertension (PAH) risk assessment on the management of disease, researchers designed a modified Risk Assessment Score of PAH (mRASP) comprising four non-invasive variables—World Health Organization functional class, 6-min walk distance, N-terminal of the pro-hormone brain natriuretic peptide, and right atrial area—for effective, practical, daily use in a clinical setting. They performed validation of the score in the prediction of 1-year survival rate for patients with PAH by contrast with the REVEAL risk score. Displaying similar predictive power and accuracy, with extra simplicity and convenience, when compared with the REVEAL score, outcomes supported mRASP as an eligible risk assessment tool for the prognostic assessment of PAH.